Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis

Published:2022-03 Issue: Volume:104 Page:102352
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Villacampa Guillermo^ORCID,Tolosa Pablo,Salvador Fernando,Sánchez-Bayona Rodrigo,Villanueva Lorea,Dienstmann Rodrigo,Ciruelos Eva,Pascual Tomas

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference37 articles.

1. Measures of outcome in metastatic breast cancer: insights from a real-world scenario;Bonotto;Oncologist,2014

2. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial;Gligorov;Lancet Oncol,2014

3. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses;Brodowicz;Br J Cancer,2014

4. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

5. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial;Loi;Ann Oncol,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer;Scientific Reports;2024-05-29

2. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis;International Immunopharmacology;2024-05

3. Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis;Frontiers in Oncology;2024-02-09

4. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple‐negative breast cancer: A systematic review and meta‐analysis;Cancer Medicine;2023-12

5. The specific viral composition in triple-negative breast cancer tissue shapes the specific tumor microenvironment characterized on pathological images;Microbial Pathogenesis;2023-11